Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

3.3%

1 terminated/withdrawn out of 30 trials

Success Rate

95.7%

+9.1% vs industry average

Late-Stage Pipeline

57%

17 trials in Phase 3/4

Results Transparency

14%

3 of 22 completed trials have results

Key Signals

4 recruiting3 with results

Enrollment Performance

Analytics

Phase 3
13(46.4%)
Phase 2
7(25.0%)
Phase 1
4(14.3%)
Phase 4
4(14.3%)
28Total
Phase 3(13)
Phase 2(7)
Phase 1(4)
Phase 4(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (30)

Showing 20 of 30 trials
NCT07216430Phase 2Recruiting

Safety and Efficacy of wSp Vaccine in Young Children

Role: collaborator

NCT06507605Phase 1Completed

Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African Adults

Role: lead

NCT07379151Not Yet Recruiting

Evaluation of the Antibody Persistence Beyond Five Years After Immunization With MenFiveTM (NmCV-5), a Pentavalent Meningococcal ACYWX Conjugate Vaccine

Role: lead

NCT07147400Phase 2Recruiting

Pfs230D1 + R21 in Matrix-M1 in African School Children and Adults

Role: lead

NCT07009847Recruiting

An Observational Study to Assess Effectiveness and Safety of The R21/Matrix-M Malaria Vaccine

Role: lead

NCT03295318Phase 2Completed

Clinical Study of Meningococcal ACYWX Conjugate Vaccine, in 12-16 Month Olds

Role: lead

NCT03152903Phase 2Completed

Study to Check the Efficacy and Safety of Recombinant BCG Vaccine in Prevention of TB Recurrence

Role: lead

NCT05421611Phase 3Completed

A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL

Role: lead

NCT04351685Phase 3Completed

Evaluation of Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Tb Infection in Infants

Role: lead

NCT06281119Phase 3Not Yet Recruiting

Clinical Study to Evaluate SIIPL QHPV Vaccine (CERVAVAC®) in Women Living with HIV Aged 15-25 Years

Role: lead

NCT06413121Phase 3Recruiting

Clinical Study to Assess the Immunogenicity and Safety of Hexavalent Vaccine Containing Reduced Dose IPV

Role: lead

NCT04035278Phase 1Completed

A Phase 1 Safety Study of Dengusiil in Healthy Adults

Role: lead

NCT05447377Phase 3Unknown

A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL® In Healthy Infants

Role: lead

NCT05163561Phase 3Completed

Evaluation of Safety and Immunogenicity of Inactivated Adjuvanted Polio Vaccine in Comparison With Licensed Inactivated Poliovirus Vaccine

Role: lead

NCT02145000Phase 3Completed

Efficacy and Safety of a Pentavalent Rotavirus Vaccine (BRV-PV) Against Severe Rotavirus Gastroenteritis in Niger

Role: collaborator

NCT03896477Phase 3Completed

Study of 10-valent Pneumococcal Conjugate Vaccine (Pneumosil) Administered in a 2+1 Schedule to Healthy Infants

Role: collaborator

NCT04439045Phase 3Completed

Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 (COVID-19) Infection Rate and Severity

Role: collaborator

NCT04358731Phase 2Completed

Study to Evaluate the Lot to Lot Consistency of SIIPL Meningococcal ACYWX Conjugate Vaccine and to Compare Its Safety and Immunogenicity With That of Licensed Meningococcal ACWY Vaccine Menactra® in Healthy Individuals 18-85 Years of Age

Role: lead

NCT03656198Phase 4Completed

Non-specific Effects of Rabies Vaccine

Role: collaborator

NCT03964012Phase 3Completed

Study to Assess Immunegnicity & Safety of Pentavalent Meningococcal Vaccine (NmCV-5)

Role: lead